Congenital syphilis laboratory findings

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2]; Aditya Govindavarjhulla, M.B.B.S. [3]

Congenital infections Main Page

Congenital syphilis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital Syphilis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Congenital syphilis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Congenital syphilis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congenital syphilis laboratory findings

CDC on Congenital syphilis laboratory findings

Congenital syphilis laboratory findings in the news

Blogs on Congenital syphilis laboratory findings

Directions to Hospitals Treating Congenital syphilis

Risk calculators and risk factors for Congenital syphilis laboratory findings

Laboratory Findings

Infants delivered of women with a reactive STS should have a cerebrospinal fluid (CSF) evaluation in any of the following circumstances:

  • The infant shows any signs compatible with congenital syphilis OR
  • Maternal therapy was inadequate, unknown, or it occurred late (greater than or equal to 20 weeks) in pregnancy OR
  • Maternal therapy did not include penicillin OR
  • Adequate follow-up cannot be ensured

Other living infants with a diagnosis of confirmed or compatible congenital syphilis should have a CSF examination before treatment to provide a baseline for follow-up examination. Although the importance of the CSF examination is debated, a quantitative VDRL CSF test can be meaningful if it is done in conjunction with tests for elevated total protein and lymphocyte count. The RPR card test should not be used for CSF evaluation.

Regardless of CSF results, however, all children with a diagnosis of confirmed or compatible congenital syphilis should be treated with a regimen effective for neurosyphilis.

Evaluation in the First Month of Life

All infants born to mothers who have reactive nontreponemal and treponemal test results should be evaluated with a quantitative nontreponemal serologic test (RPR or VDRL) performed on infant serum, because umbilical cord blood can become contaminated with maternal blood and yield a false-positive result. Conducting a treponemal test (i.e., TP-PA, FTA-ABS, EIA, or chemiluminescence assay) on a newborn’s serum is not necessary.

Serology

The diagnosis of congenital syphilis is complicated by the transplacental transfer of maternal nontreponemal and tre-ponemal IgG antibodies to the fetus. This transfer of antibodies makes the interpretation of reactive serologic tests for syphilis in infants difficult.

All infants born to mothers who have reactive nontreponemal and treponemal test results should be evaluated with a quantitative nontreponemal serologic test (RPR or VDRL) performed on infant serum because umbilical cord blood can become contaminated with maternal blood and could yield a false-positive result. Conducting a treponemal test (i.e., TP-PA or FTA-ABS) on a newborn’s serum is not necessary. No commercially available immunoglobulin (IgM) test can be recommended.

Dark Microscopic Examination

Darkfield microscopic examination or DFA staining of suspicious lesions or body fluids (e.g., nasal discharge) also should be performed.

Standard Tests

  • Antibody Confirmatory Tests (treponemal)
    • Fluorescent treponemal antibody absorption (FTA-ABS)
    • Fluorescent treponemal antibody absorption double staining (FTA-ABS DS)
    • Microhemagglutination assay for antibody to T. pallidum (MHA-TP)
    • Hemagglutination treponemal test for syphilis (HATTS)
    • Bio-enzaBead Test (ELISA)

Non Standard Tests

  • FTA-ABS immunoglobulin (IgM)
  • FTA-ABS 19S IgM
  • IgM capture ELISA

References


Template:WikiDoc Sources